In this trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab than with …

CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical …

Nivolumab was investigated in CHECKMATE-274 (NCT02632409), a randomized, double-blind, placebo-controlled trial in patients who were within 120 days of radical resection of UC of the …

In the phase 3, randomized, double-blind CheckMate 274 trial, 1 adjuvant nivolumab demonstrated statistically significant and clinically meaningful disease free survival benefit …

We report efficacy and safety with extended follow-up, and exploratory biomarker analyses from the phase II CheckMate 275 trial to identify biomarkers of response to nivolumab in platinum …

In a new analysis, investigators sought to determine how many patients with high-risk muscle-invasive urothelial carcinoma who underwent radical cystectomy could be cured with adjuvant …

CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult …

We report results at an extended median follow-up of 36.1 months in the ITT population. In addition, we report interim overall survival (OS) data for the first time and an exploratory …

In the CheckMate-274 trial that compared adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, the magnitude of benefit …

In this phase 3, multinational, open-label trial, we randomly assigned patients with previously untreated unresectable or metastatic urothelial carcinoma either to receive intravenous …